 Can-Fite BioPharma Ltd. NYSE American: CANF TASE:CFBI, a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, announced today it is implementing an interim analysis of the Phase III ComfortTM trial designed to evaluate the Companys drug candidate, Piclidenoson, in the treatment of moderate-to-severe plaque psoriasis. Following the independent data monitoring committees evaluation of the data, Can-Fite expects to announce interim results in the fourth quarter of 2020. 